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119Role of cardiac evaluation before thoracic
endovascular aortic repair
Asvin M. Ganapathi, MD,a Brian R. Englum, MD,a Matthew A. Schechter, MD,a John P. Vavalle, MD,b
J. Kevin Harrison, MD,b Richard L. McCann, MD,c and G. Chad Hughes, MD,a Durham, NC
Background: Patients with thoracic aortic disease undergoing thoracic endovascular aortic repair (TEVAR) often
have concomitant coronary artery disease and are at risk for perioperative adverse cardiac events. Despite this risk, the
need for and extent of preoperative cardiac workup before TEVAR remain undeﬁned. This study seeks to assess the
adequacy of a limited cardiac evaluation before TEVAR, including assessment of cardiac symptoms, resting electrocar-
diography (ECG), and transthoracic echocardiography (TTE), as well as to estimate the incidence of perioperative cardiac
events in patients undergoing TEVAR.
Methods: Retrospective analysis of a prospectivelymaintained Institutional ReviewBoard-approved databasewas performed
for all patients undergoing TEVAR at a single referral institution betweenMay 2002 and June 2013. The analysis identiﬁed
463 TEVAR procedures. All procedures involving median sternotomy were excluded, and 380 procedures (343 patients)
were included in the ﬁnal analysis. Degree of cardiac workup was classiﬁed on the basis of the highest level of preoperative
testing: no workup, resting ECG only, resting TTE, exercise/pharmacologic stress testing, or coronary angiography.
Standard workup consisted of cardiac symptom assessment alongwith resting ECGor TTE, with further workup indicated
for unstable symptoms, signiﬁcantly abnormal ﬁndings on ECG or TTE, or multiple cardiac risk factors. Categorical and
continuous variables were compared by Fisher’s exact test and analysis of variance, respectively.
Results: No preoperative cardiac workup was performed for 28 patients (7.4%); 127 patients (33.4%) had resting ECG
only, 208 patients (54.7%) had resting echocardiography, 12 patients (3.2%) underwent stress testing, and ﬁve patients
(1.3%) had coronary angiography. Patients undergoing stress testing or coronary angiography were older and had a
higher incidence of known coronary artery disease (P < .01) and prior myocardial infarction (P[ .01). Complex hybrid
aortic repairs and TEVAR for aneurysmal disease were more likely to have an extensive workup, whereas nonelective
procedures more commonly had no workup. A total of nine patients (2.4%) experienced a perioperative cardiac event
(myocardial infarction or cardiac arrest), with no signiﬁcant difference noted among all groups (P[ .45), suggesting that
the extent of cardiac workup was appropriate. The incidence of 30-day/in-hospital mortality (5.5%) and cardiac-speciﬁc
mortality (0.8%) was similar among all groups.
Conclusions: The risk of a postoperative cardiac event after TEVAR is low (2.4%), and initial screening with either resting
TTE or ECG, in addition to assessment of cardiac symptom status, appears adequate for most TEVAR patients. As such,
we recommend resting TTE or ECG as the initial cardiovascular screening mechanism in patients undergoing TEVAR,
with subsequent more invasive studies if initial screening reveals cardiovascular abnormalities. (J Vasc Surg
2014;60:1196-203.)The incidence of cardiac events such as arrhythmias,
myocardial infarction (MI), and cardiac-related morbidity
is increased in patients undergoing major vascular surgery
with rates ranging from 5% to 15%.1-4 This increased inci-
dence of cardiac morbidity and mortality is believed to be
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6factors, such as coronary artery disease (CAD), congestive
heart failure, hypertension, hyperlipidemia, and diabetes,
among the vascular surgery population.2,5 Patients under-
going thoracic aortic surgery are no exception and repre-
sent one of the highest risk groups for perioperative
cardiac events.6
Given this potential for cardiac morbidity and mortality
after major vascular surgery, many studies have examined
patient risk stratiﬁcation and methods of prevention of
adverse cardiac events.7,8 Previous literature focusing on
risk stratiﬁcation has used a variety of methods ranging
from simple scoring systems, such as the Eagle or Lee
criteria, to complex metrics, such as preoperative cardiopul-
monary exercise testing.2,9,10 In addition, certain studies
have focused on the need for assessment and treatment
of coronary stenosis for prevention of perioperative cardiac
events.11,12 However, the majority of these studies have
included primarily abdominal vascular surgical procedures,
only elective cases, or have grouped both open and endo-
vascular repairs. Further, although patients undergoing
thoracic aortic surgery are thought to be at particular
risk for perioperative cardiac events,6 there are data
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be reduced with endovascular compared with open sur-
gery (in abdominal aortic procedures),3 and to date a
consensus algorithmic approach to cardiac workup before
thoracic endovascular aortic repair (TEVAR) has not
been deﬁned. Further, the exact cardiac risk associated
with TEVAR has not been well characterized.
From the inception of our institutional TEVAR pro-
gram, we have used a limited cardiac evaluation before
TEVAR including assessment of cardiac symptoms, resting
electrocardiography (ECG), and transthoracic echocardi-
ography (TTE), although this approach has not been sys-
tematically studied to date. Further, because unnecessary
preoperative workup can lead to delays in surgery and
increased health care costs, a better understanding of the
optimal cardiac evaluation for TEVAR patients is essential.
As such, the purpose of this study was to assess the efﬁcacy
of a limited preoperative cardiovascular workup before
TEVAR as well as to assess the incidence of adverse cardiac
events after TEVAR.
METHODS
Patients and data source. A retrospective review was
performed of prospectively collected data from all patients
undergoing TEVAR at a single referral institution. Preop-
erative, intraoperative, and postoperative variables were
abstracted from the Duke Thoracic Aortic Surgery Data-
base, a prospectively maintained clinical registry of all
patients who have undergone thoracic aortic surgery at
Duke University Medical Center (Durham, NC). The
study was reviewed and approved by the Duke University
Institutional Review Board, and the need for individual
patient consent was waived.
Inclusion criteria included any patient undergoing
TEVAR since program inception in May 2002 through
June 2013. Any patient who underwent concomitant me-
dian sternotomy as part of the TEVAR procedure was
excluded from analysis. After query of the database, 463
TEVAR procedures were identiﬁed, of which 380 (343
patients) met study criteria. Comorbidities and patient
characteristics were deﬁned by the Society of Thoracic
Surgeons deﬁnitions.13 Patients were stratiﬁed on the basis
of the degree of preoperative cardiac workup they received.
Examination of patient medical records, including admis-
sion history and physical examination, clinic notes, radi-
ology, cardiac catheterization, and transfer records, was
used to determine the extent of preoperative workup
performed. The groups identiﬁed, in order of invasiveness,
were no workup, resting ECG, resting TTE, exercise/
pharmacologic stress testing, and coronary angiography.
In cases in which multiple procedures were performed,
patients were assigned to the group according to the high-
est level of preoperative workup received. Only tests per-
formed as part of the preoperative workup for the
TEVAR procedure were included for analysis.
Preoperative cardiac evaluation. Our institutional
algorithm for pre-TEVAR cardiac workup consisted of
assessment of cardiac symptoms with clinical history andphysical examination in all patients. Patients undergoing
elective cases were then subject to resting ECG or TTE.
In cases of multiple cardiac risk factors, unstable patient
symptoms such as low-level exertional or resting angina, or
markedly abnormal ﬁndings on ECG or TTE, further
evaluation of the patient’s cardiac status was undertaken
(Fig). For nonelective procedures, only workup that would
not delay surgery was done.
Outcomes. The primary study end point was the inci-
dence of a perioperative cardiac event, deﬁned as MI or
cardiac arrest in the overall population as well as stratiﬁed
by degree of cardiac workup performed. MI was deﬁned
by the occurrence of ST changes on ECG with accompa-
nying rise of cardiac biomarkers.14 Secondary outcomes
included 30-day/in-hospital and cardiac-speciﬁc mortality
for both the overall population and stratiﬁed by degree of
cardiac workup.
Statistical methods. After stratiﬁcation of patients
by the level of cardiac workup received, the Fisher’s exact
test or analysis of variance, for categorical and continuous
variables, respectively, was used for comparison of patient
and procedural characteristics and the aforementioned
postoperative outcomes. An afﬁrmative decision was
made a priori to set the signiﬁcance level at a ¼ .05 for
all analyses. Statistical analysis was done with JMP Pro
10.0.2 (SAS Institute, Cary, NC) and R version 3.0.1
(Vienna, Austria).
RESULTS
The analysis identiﬁed 380 patients who met the study
criteria. After stratiﬁcation into the ﬁve predetermined
groups, there were 28 patients (7.4%) who received no
cardiac workup, 127 patients (33.4%) who underwent
ECG alone, 208 patients (54.7%) with TTE, 12 patients
(3.2%) with a stress test, and ﬁve patients (1.3%) with
coronary angiography (Table I). Of the 12 patients who
underwent a preoperative stress test, only one test result
was positive for inducible ischemia (right coronary distribu-
tion) and did not lead to revascularization. Of the ﬁve
patients undergoing coronary angiography, three had a
positive functional study result leading to catheterization,
whereas in two the decision was made to proceed directly
to catheterization on the basis of preoperative cardiology
consultation. Only one of the ﬁve patients undergoing
coronary angiography had subsequent revascularization;
this patient was status post two prior coronary bypass graft-
ing operations and underwent multivessel percutaneous
coronary intervention for a diseased saphenous vein graft
as well as two native vessel stenoses.
Comparison of patient characteristics revealed signiﬁ-
cant differences in age of the patients and incidence of
hypertension, hyperlipidemia, and tobacco abuse among
the groups (Table I). In all cases, as the age of the patient
and number of cardiac risk factors increased, the degree of
workup increased accordingly. Analysis of cardiac comor-
bid disease burden (Table II) demonstrated that patients
with known CAD or history of prior MI were signiﬁcantly
more likely to undergo more extensive preoperative cardiac
Fig. Schematic of algorithmic approach to limited cardiac workup for thoracic endovascular aortic repair (TEVAR)
patients. ECG, Electrocardiography; TTE, transthoracic echocardiography.
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workup in those with a history of preoperative congestive
heart failure, lower ejection fraction, or prior coronary
revascularization (Table II).
With regard to operative characteristics (Table III),
patients with more extensive cardiac workup were
more likely to have aneurysmal disease, whereas more
than half of aortic transection patients (13 of 23) did
not receive any preoperative cardiac workup. In addi-
tion, patients undergoing more extensive endovascular
procedures (hybrid thoracoabdominal aortic aneurysm
and hybrid arch repair) were more likely to have a
more extensive cardiac workup with stress test or coro-
nary angiography, and there was a trend toward more
extensive workup in those with larger preoperative aortic
diameters. Patients with no cardiac workup were more
likely to be nonelective case status (86%) and AmericanSociety of Anesthesiologists class 4. There was no signif-
icant difference among the groups with regard to
concomitant vascular procedures performed or the num-
ber of endografts implanted (Table III).
The overall incidence of perioperative MI or adverse
cardiac event (MI or cardiac arrest) was 2.4% (n ¼ 9) for
both. All adverse cardiac events involved MI, and one of
those patients also had a postoperative cardiac arrest. Of
the nine MIs, two were treated with revascularization pro-
cedures (percutaneous coronary intervention), whereas the
rest were managed medically. Patients who suffered a car-
diac event had an average of 4.2 cardiac risk factors (hyper-
tension, hyperlipidemia, smoking, diabetes, CAD, history
of MI, and peripheral vascular disease); those without an
event had an average of 2.8 risk factors (P < .01). Opera-
tive factors with prolonged operative time and extensive
blood loss appeared to play a role in two of the nine cases
Table II. Patient cardiac comorbidities
Variable
Overall
(N ¼ 380)
No workup
(n ¼ 28)
ECG only
(n ¼ 127)
TTE
(n ¼ 208)
Stress test
(n ¼ 12)
Coronary
angiography (n ¼ 5) P value
Known CAD 109 (28.7) 2 (7.1) 39 (30.7) 59 (28.4) 5 (41.7) 4 (80) .005
History of MI 46 (12.1) 1 (3.6) 10 (7.9) 29 (13.9) 4 (33.3) 2 (40) .01
Congestive heart failure 24 (6.3) 0 (0) 9 (7.1) 13 (6.2) 1 (8.3) 1 (20) .298
Ejection fraction 55 (55-55) 55 (55-55) 55 (55-55) 55 (55-55) 55 (51-55) 50 (48-52) .425
Prior coronary
revascularization
.126
None 303 (79.7) 28 (100) 102 (80.3) 162 (77.9) 8 (66.7) 3 (60)
PCI 34 (8.9) 0 (0) 16 (12.6) 15 (7.2) 2 (16.7) 1 (20)
CABG 37 (9.7) 0 (0) 7 (5.5) 27 (13) 2 (16.7) 1 (20)
CABG and PCI 6 (1.6) 0 (0) 2 (1.6) 4 (1.9) 0 (0) 0 (0)
CABG, Coronary artery bypass grafting; CAD, coronary artery disease; ECG, electrocardiography; IQR, interquartile range; MI, myocardial infarction; PCI,
percutaneous coronary intervention; TTE, transthoracic echocardiography.
Values are expressed as median (interquartile range) or number (%).
Table I. Patient characteristics
Variable
Overall
(N ¼ 380)
No workup
(n ¼ 28)
ECG only
(n ¼ 127)
TTE
(n ¼ 208)
Stress test
(n ¼ 12)
Coronary
angiography (n ¼ 5) P value
Age, years 68 (55-75) 52 (34-56) 68 (53-75) 69 (59-76) 70 (63-74) 73 (59, 76) <.001
Male sex 232 (61.1) 15 (53.6) 89 (70.1) 118 (56.7) 6 (50) 4 (80) .081
BMI 27.8 (24.4-31) 28 (24-31) 29 (25-31) 27 (24-30) 29 (26-33) 28 (24-30) .692
White race 245 (64.5) 13 (46.4) 90 (70.9) 130 (62.5) 8 (66.7) 4 (80) .126
Hypertension 329 (86.6) 14 (50) 114 (89.8) 187 (89.9) 9 (75) 5 (100) <.001
Hyperlipidemia 220 (57.9) 7 (25) 76 (59.8) 122 (58.7) 10 (83.3) 5 (100) <.001
Tobacco abuse 230 (60.5) 10 (35.7) 67 (52.8) 140 (67.3) 10 (83.3) 3 (60) .001
Diabetes mellitus 57 (15) 2 (7.1) 18 (14.2) 33 (15.9) 3 (25) 1 (20) .53
Peripheral vascular disease 97 (25.5) 3 (10.7) 34 (26.8) 54 (26) 3 (25) 3 (60) .152
Baseline creatinine
level >1.5 mg/dL
100 (26.3) 4 (14.3) 39 (30.7) 53 (25.5) 2 (16.7) 2 (40) .326
History of stroke or TIA 41 (10.8) 2 (7.1) 11 (8.7) 24 (11.5) 3 (25) 1 (20) .299
COPD 101 (26.6) 4 (14.3) 36 (28.3) 53 (25.5) 7 (58.3) 1 (20) .074
BMI, Body mass index; COPD, chronic obstructive pulmonary disease; ECG, electrocardiography; IQR, interquartile range; TIA, transient ischemic attack;
TTE, transthoracic echocardiography.
Values are expressed as median (interquartile range) or number (%).
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MIs occurred in the TTE group (n ¼ 8; 3.8%). The
same held true for cardiac events, with all but one of the
cardiac events occurring in the TTE group (n ¼ 8;
3.8%), and all patients suffering a cardiac event had an
abnormal ﬁnding on preoperative ECG or TTE. However,
the abnormalities were generally nonspeciﬁc and mild and,
consequently, did not lead to referral for a higher level of
preoperative testing.
Only three instances (0.8%) of 30-day/in-hospital
cardiac-speciﬁc mortality occurred, with one event (0.8%)
in the ECG-only group and two occurrences in the TTE
group (1.0%). Two of the three cardiac deaths followed
nonelective procedures. Overall, 5.5% (n ¼ 21) of all
patients died within 30 days or in the hospital. Of the
18 patients who died of a noncardiac event, the majority
of deaths were secondary to multisystem organ failure
due to complications of the underlying aortic disease or
the procedure itself. Notably, there were no instances of
adverse cardiac events or cardiac-speciﬁc or any-causemortality in the no-workup, stress test, or coronary angiog-
raphy groups. Further, there were no signiﬁcant differences
between subgroups of workup extent for any of the
analyzed outcomes (Table IV).
DISCUSSION
Because of the signiﬁcant incidence of cardiac
morbidity and mortality after major vascular surgery, pre-
operative cardiac risk stratiﬁcation is thought to be impor-
tant6,9,15 as it may allow identiﬁcation of those patients at
highest risk for a perioperative cardiac event. Further, the
information gained through the risk stratiﬁcation process
can help guide patient management during and after sur-
gery, which also may lead to better outcomes. However,
unwarranted cardiac workup not only increases health
care costs but has the potential to delay surgery. Previous
data examining methods of risk stratiﬁcation have focused
primarily on abdominal or peripheral vascular surgery or
elective surgery and have not assessed the extent of cardiac
workup required for patients undergoing TEVAR
Table III. Operative characteristics
Variable
Overall
(N ¼ 380)
No workup
(n ¼ 28)
ECG only
(n ¼ 127)
TTE
(n ¼ 208)
Stress test
(n ¼ 12)
Coronary
angiography (n ¼ 5) P value
Nonelective procedure
status
148 (38.9) 24 (85.7) 54 (42.5) 66 (31.7) 3 (25) 1 (20) <.001
Procedure performed .005
Isolated descending 288 (75.8) 26 (92.9) 107 (84.3) 145 (69.7) 7 (58.3) 3 (60)
Hybrid TAAA 65 (17.1) 1 (3.6) 16 (12.6) 42 (20.2) 5 (41.7) 1 (20)
Hybrid arch 27 (7.1) 1 (3.6) 4 (3.1) 21 (10.1) 0 (0) 1 (20)
Aortic disease <.001
Aneurysm 230 (60.5) 7 (25) 75 (59.1) 131 (63) 12 (100) 5 (100)
Acute dissection 54 (14.2) 6 (21.4) 20 (15.7) 28 (13.5) 0 (0) 0 (0)
Chronic dissection 73 (19.2) 2 (7.1) 24 (18.9) 47 (22.6) 0 (0) 0 (0)
Traumatic transection 23 (6.1) 13 (46.4) 8 (6.3) 2 (1) 0 (0) 0 (0)
ASA class <.001
2 3 (0.8) 0 (0) 1 (0.8) 1 (0.5) 0 (0) 1 (20)
3 226 (59.5) 7 (25) 66 (52) 146 (70.2) 6 (50) 1 (20)
4 151 (39.7) 21 (75) 60 (47.2) 61 (29.3) 6 (50) 3 (60)
Number of endografts
implanted
2 (1-2) 1 (1-2) 1 (1-2) 2 (1-2) 2 (1-2) 2 (2-2) .202
Maximal aortic diameter 5.8 (4.8-6.6) 5 (4-7) 6 (4-6) 6 (5-7) 6 (5-6) 7 (7-7) .056
Concomitant procedure 156 (41.1) 8 (28.6) 45 (35.4) 94 (45.2) 6 (50) 3 (60) .181
ASA, American Society of Anesthesiologists; ECG, electrocardiography; TAAA, thoracoabdominal aortic aneurysm; TTE, transthoracic echocardiography.
Values are expressed as median (interquartile range) or number (%).
Table IV. Perioperative outcomes
Variable
Overall
(N ¼ 380)
No workup
(n ¼ 28)
ECG only
(n ¼ 127)
TTE
(n ¼ 208)
Stress test
(n ¼ 12)
Coronary
angiography (n ¼ 5) P value
Postoperative cardiac eventa 9 (2.4) 0 (0) 1 (0.8) 8 (3.8) 0 (0) 0 (0) .449
Postoperative MI 9 (2.4) 0 (0) 1 (0.8) 8 (3.8) 0 (0) 0 (0) .449
Thirty-day/in-hospital death 21 (5.5) 0 (0) 9 (7.1) 12 (5.8) 0 (0) 0 (0) .668
Thirty-day/in-hospital cardiac death 3 (0.8) 0 (0) 1 (0.8) 2 (1) 0 (0) 0 (0) .999
ECG, Electrocardiography; MI, myocardial infarction; TTE, transthoracic echocardiography.
Values are expressed as number (%).
aDeﬁned as MI or cardiac arrest.
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dence of adverse cardiac events after TEVAR is low
(2.4%) and that a limited cardiac workup, consisting of a
preoperative assessment with history and physical examina-
tion along with resting ECG and TTE in asymptomatic pa-
tients, appears adequate in most individuals.
Given the importance of preventing cardiac events in
patients undergoing vascular surgery, a signiﬁcant amount
of literature has been devoted to the topic. The 2010
American College of Cardiology/American Heart Associa-
tion guidelines for thoracic aortic disease recommend addi-
tional studies to determine the presence of signiﬁcant CAD
in the setting of symptoms of myocardial ischemia as well as
additional testing to quantitate a patient’s comorbid state
before thoracic aortic procedures.15 These recommenda-
tions, however, do not provide a clear algorithmic approach
to cardiac workup before TEVAR and apply to both open
and endovascular procedures. Given the decreased periop-
erative cardiac risk associated with endovascular vs open
surgery,16 it is unclear if guidelines for patients undergoing
TEVAR should differ from those for patients undergoing
open thoracic aortic repair, especially because major openthoracic aortic surgery is considered to have the highest
risk for cardiac morbidity and mortality.15
Although no studies to date have examined the inci-
dence of cardiac events and the extent of preoperative car-
diac workup required before TEVAR, there are several
studies in the literature concerning cardiac evaluation in pa-
tients undergoing abdominal aortic aneurysm repair that
provide useful data for comparison. Troisi et al3 described
an experience similar to the current study in which 531
open or endovascular elective abdominal aortic aneurysm
repair patients underwent preoperative screening with
ECG, TTE, and cardiology consultation. Nearly two thirds
of the patients underwent a stress test, with only 25% hav-
ing a positive test result. Of those with a positive stress test
result, nearly 40% underwent subsequent coronary angiog-
raphy, with 38% having subsequent coronary revasculariza-
tion. The incidence of cardiac morbidity and mortality was
6.8% and 0.6%, respectively. Thus, even though the major-
ity of patients in the Troisi study underwent stress testing,
only 3.7% had a subsequent revascularization procedure,
similar to the low incidence of preoperative revasculariza-
tion performed in the current study before TEVAR.
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repair of thoracoabdominal and juxtarenal aneurysms
with branched/fenestrated endografts. They observed
MIs in 7.7% of patients and a cardiac-related mortality of
2%. Notably, all patients had serial postoperative troponin
measurements, and MI was deﬁned by consensus criteria.
A preoperative stress test was performed in 73% of patients,
of which 85% had normal ﬁndings. Thus, the results of
the Bub study support the ﬁndings of the current study
in that the use of stress testing would appear to be without
merit in most patients. Finally, speciﬁc to TEVAR, Chung
et al18 found that cardiac mortality was 1.8% and 4.8%
at <30 days and >30 days, respectively; however, they
did not describe their method of risk stratiﬁcation or car-
diac workup. As a whole, these prior studies demonstrate
cardiac event rates and mortality risks similar to those pre-
sented in this study and also support the use of a more
limited cardiac workup with ECG and TTE before TEVAR
with the avoidance of stress testing or coronary angiog-
raphy in most patients.
The role of coronary revascularization before major
vascular surgery has been examined as a method to limit
cardiac morbidity and mortality. Initially, it was believed
that coronary revascularization should be done before ma-
jor vascular surgery19,20; however, this paradigm was called
into question by the Coronary Artery Revascularization
Prophylaxis (CARP) trial and other studies.11,21 Whereas
some of these studies were criticized because of revasculari-
zation of low-risk cardiac patients, Poldermans et al12
conducted a randomized controlled trial of only high-risk
cardiovascular patients and demonstrated that coronary
revascularization before major vascular surgery did not
provide a short- or long-term survival advantage. In addition,
should a coronary stent be placed for revascularization, the
issues of dual antiplatelet therapy and potential delay of sur-
gery must be considered.2,22 These data suggesting preoper-
ative revascularization to be of questionable beneﬁt would
also appear to support the currently proposed algorithm of
limited cardiac evaluationbeforeTEVAR,which led topreop-
erative coronary angiography in only 1.3% of patients.
By starting with a limited cardiac workup before
TEVAR, unnecessary tests are avoided in the majority of
patients. However, this approach emphasizes the impor-
tance of a careful history and physical examination, which
is essential to determine whether further workup is neces-
sary, and ﬁndings such as congestive heart failure symptoms
or angina should prompt further evaluation. In addition,
the preoperative ECG and TTE can provide valuable infor-
mation about a patient’s cardiac status, with Q waves or
bundle branch block on ECG or focal wall motion abnor-
malities, reduced ventricular function, or signiﬁcant
valvular disease on TTE, for example, indicating patients
in whom additional workup may be indicated. Whereas
other groups have incorporated cardiology evaluation as
part of the standard preoperative cardiac workup, our prac-
tice is to refer patients for cardiology evaluation only in the
case of an abnormality detected on initial limited workup.
On the basis of the low incidence of cardiac events andmortality observed with this approach, we think this prac-
tice is safe and saves health system resources and time.
Another issue that was not addressed in this paper but
is important to the prevention of perioperative cardiovascu-
lar events is optimization of medical therapy in the periop-
erative period. Before elective surgery, elements of lifestyle
modiﬁcation as well as addressing patient comorbidities
have been demonstrated to reduce cardiac events.9 Modiﬁ-
able factors include smoking cessation, strict glycemic con-
trol for diabetics, control of hypertension, and, perhaps
most important, the use of statins. Randomized data
from Durazzo et al23 revealed a threefold decrease in car-
diac events for patients who took 20 mg of atorvastatin,
regardless of lipid status, for at least 30 days before major
vascular surgery compared with placebo. O’Neill et al24
also demonstrated a protective effect of statins in the peri-
operative phase. Moreover, others have shown that abrupt
perioperative withdrawal of statins can lead to an increase
in the incidence of adverse cardiac events.25,26 The use of
b-blockers can also help decrease perioperative cardiac
risk, particularly if a long-acting agent is initiated before
surgery.27 However, recent studies have established that
b-blockers should be employed only in high-risk patients
or as continuation for patients already receiving a b-
blocker.28,29 Speciﬁcally, they should not be used in inter-
mediate- or low-risk vascular surgery patients.9
Also warranting discussion are the three cardiac deaths
that occurred. Two of the patients who suffered a cardiac
death were urgent cases performed for impending aortic
rupture. In both cases, there was a signiﬁcant cardiac his-
tory; one patient had an ejection fraction of 30% as well
as a history of MI, whereas the other patient had a history
of CAD with coronary artery bypass grafting more than
30 years before her TEVAR procedure. The workup for
the ﬁrst patient was ECG and TTE; the second patient
had only ECG. However, the urgent nature of their cases
precluded further workup as surgical delay was thought
to be risk prohibitive. These two deaths highlight the fact
that close attention should be paid to patients undergoing
nonelective TEVAR, particularly those with cardiac risk
factors, in the perioperative period. The third cardiac death
occurred in a patient with an extensive cardiac history (two
previous MIs, history of coronary artery bypass grafting on
two separate occasions, congestive heart failure symptoms
at presentation) who underwent an elective hybrid thora-
coabdominal aortic aneurysm repair. His workup also con-
sisted of only ECG and TTE; he had no unstable
symptoms by history, and his ejection fraction was 50%
by TTE. However, he suffered a perioperative MI with
fatal cardiac arrest. It is unknown if he would have
beneﬁted from a more extensive workup, but on the basis
of the size of his aneurysm, the risk of rupture without
repair was considered very high.
Limitations. The current study has several notable
limitations. First, given the observational, nonrandomized
nature of the study, true head-to-head comparison of the
various approaches to preoperative cardiac evaluation was
not performed. In addition, the overall study cohort was
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no workup, a stress test, or coronary angiography, thus
limiting the sample size of each of these groups. Similarly,
there were few cardiac events, which prevented adjustment
for other patient risk factors that may have inﬂuenced the
results presented. Moreover, as this was a single-institution
study, there is the possibility of a selection bias in the pa-
tient cohort selection that may have inﬂuenced both the
outcomes presented and subsequent analyses.
CONCLUSIONS
The risk of a postoperative cardiac event after TEVAR
is low (2.4%), and initial screening with either resting TTE
or ECG, in addition to assessment of cardiac symptom
status and physical examination, appears adequate for
most TEVAR patients. As such, we recommend resting
TTE or ECG as the initial cardiovascular screening mech-
anism in patients undergoing TEVAR, with subsequent
more invasive studies if initial screening reveals signiﬁcant
cardiovascular abnormalities.
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Submitted Jan 18, 2014; accepted May 16, 2014.DISCUSSIONDr Eugene M. Langan III (Greenville, SC). This is an inter-
esting paper from the Division of Cardiovascular and Thoracic
Surgery at Duke University. The premise of this study is that for
selected patients undergoing thoracic endovascular aortic repair
(TEVAR), preoperative cardiac workup can be limited to a history
and physical, electrocardiography, and transthoracic echocardiog-
raphy. The study’s primary end point was deﬁned as myocardial
infarction or cardiac arrest, interestingly not death.
Their results reveal a myocardial infarction or cardiac arrest
rate of 2.4% or nine of 380 patients. There were 21 or 5.5%
patient deaths within 30 days or within the hospital stay. Three
of the deaths were cardiac in etiology.
I have three questions for the authors:
1. It would seem to me that the type of anesthesia used would
affect the perioperative stress levels and therefore potential
cardiac risk to the patient, yet you do not include anything
about the type of anesthesia. Can you please comment on this?
2. I understand that death was not part of this study’s end point,
but can you still comment on the other 18 noncardiac deaths?
3. In the manuscript, you suggest a limited cardiac workup
to avoid delay of surgical repair but then recommend 30-day
preoperative statin therapy. This does not make sense. Please
explain.
I would like to thank the Association for the privilege of the
ﬂoor and allowing me to open this discussion.
Dr Asvin M. Ganapathi. Regarding the ﬁrst question, all
patients in this study underwent general anesthesia under the
oversight of a cardiothoracic specialty-trained anesthesiologist.We believe that general anesthesia is useful in these patients as it
eliminates problems with patient movement and allows accurate
and precise delivery of the stent grafts. We do not use local anes-
thesia for any TEVAR procedures, and all TEVAR procedures at
Duke are done in a hybrid operating room with cardiac anesthesi-
ology, intraoperative transesophageal echocardiographic moni-
toring, and general anesthesia. We believe that this approach is
safe on the basis of the low incidence of perioperative cardiac
events detailed in this study.
With regard to the second question about the non-cardiac-
related deaths, of the 18 noncardiac deaths, there were multiple
causes. The primary cause of death after TEVAR was perioperative
complications related to patient comorbidities or the underlying
aortic disease process.
Finally, concerning the third question, in the manuscript we
mention the use of preoperative statin therapy; however, we are
not suggesting that every patient be prescribed 30 days of statin
therapy preoperatively before proceeding with TEVAR. Rather,
we mention this as it has been detailed in the literature as a known
therapy with the potential to reduce perioperative cardiac
morbidity and mortality. For elective cases in which the patient
is not already receiving a statin, we generally will initiate statin
therapy at the time the patient is evaluated in the outpatient
setting; however, we will not do this at the cost of delaying
surgery. In addition, for nonelective cases, the limited cardiac
workup protocol is employed if the patient is stable. We do not
advocate for delay of surgery to initiate medical therapy in the
nonelective scenario.
